Understanding the mechanisms of post-ischemic inflammation, particularly involving IL-1β and NLRP3, is crucial for developing effective therapies to mitigate tissue damage and improve prognosis in ischemic heart disease patients. Here, IL1B is linked to coronary artery disorder.